Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome

Annals of Clinical Microbiology and Antimicrobials

Volumn 13, Issue 1, 2014, Pages

  Boltin, Doron ^b   Perets, Tsachi Tsadok ^a   Shporn, Einav ^a   Aizic, Shoshana ^b   Levy, Sigal ^c   Niv, Yaron ^b   Dickman, Ram ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ACADEMIC COLLEGE OF TEL AVIV YAFFO   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; LACTULOSE; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYDROGEN BREATH TEST; IRRITABLE COLON; LACTULOSE HYDROGEN BREATH TEST; MALABSORPTION; MALE; PROSPECTIVE STUDY; SMALL INTESTINAL BACTERIAL OVERGROWTH; AGED; BREATH ANALYSIS; DYSBIOSIS; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SMALL INTESTINE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; BREATH TESTS; COHORT STUDIES; DYSBIOSIS; FEMALE; HUMANS; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; LACTULOSE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME;

EID: 84925884880     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-014-0049-x     Document Type: Article

References (34)

1. Dukowicz AC, Lacy BE, Levine GM: Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 2007, 3:112-122.
2. American Gastroenterological Association medical position statement: Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1461-1463.
3. Ghoshal UC: How to interpret hydrogen breath tests. J Neurogastroenterol Motil 2011, 17:312-317.
4. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
5. Jolley J: High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011, 4:43-48.
6. Lombardo L, Foti M, Ruggia O, Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010, 8:504-508.
7. Meyrat P, Safroneeva E, Schoepfer AM: Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012, 36:1084-1093.
8. Cuoco L, Salvagnini M: Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006, 52:89-95.
9. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW: Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007, 333:266-270.
10. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A: Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009, 15:2628-2631.
11. Ford AC, Spiegel BM, Talley NJ, Moayyedi P: Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and metaanalysis. Clin Gastroenterol Hepatol 2009, 7:1279-1286.
12. Menees SB, Maneerattannaporn M, Kim HM, Chey WD: The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012, 107:28-35. quiz 36.
13. Grace E, Shaw C, Whelan K, Andreyev HJ: Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013, 38:674-688.
14. Sperber AD, Shvartzman P, Friger M, Fich A: A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the true prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 2007, 19:441-447.
15. Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC: The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996, 91:1795-1803.
16. Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G: Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007, 25:237-240.
17. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22:1157-1160.
18. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 22:31-35.
19. Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009, 18:349-358.
20. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995, 49:467-484.
21. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, TARGET Study Group: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011, 364:22-32.
22. Reischer GH, Ebdon JE, Bauer JM, Schuster N, Ahmed W, Aström J, Blanch AR, Blöschl G, Byamukama D, Coakley T, Ferguson C, Goshu G, Ko G, de Roda Husman AM, Mushi D, Poma R, Pradhan B, Rajal V, Schade MA, Sommer R, Taylor H, Toth EM, Vrajmasu V, Wuertz S, Mach RL, Farnleitner AH: Performance Characteristics of qPCR Assays Targeting Human-and Ruminant-Associated Bacteroidetes for Microbial Source Tracking across Sixteen Countries on Six Continents. Environ Sci Technol 2013, 47:8548-8556.
23. Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A: Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013, 17:1314-1320.
24. Collins BS, Lin HC: Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011, 52:382-386.
25. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F, Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F: Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin 2000, 16:14-20.
26. Stoicescu A, Andrei M, Becheanu G, Stoicescu M, Nicolaie T, Diculescu M: Microscopic colitis and small intestinal bacterial overgrowth-diagnosis behind the irritable bowel syndrome? Rev Med Chir Soc Med Nat Iasi 2012, 116:766-772.
27. Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PH: Doubleblind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci 2011, 56:2939-2946.
28. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G: Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002, 49:1582-1586.
29. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005, 11:2773-2776.
30. Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M: Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008, 103:1257-1262.
31. Furnari M, Parodi A, Gemignani L, Giannini EG, Marenco S, Savarino E, Assandri L, Fazio V, Bonfanti D, Inferrera S, Savarino V: Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010, 32:1000-1006.
32. Rosania R, Giorgio F, Principi M, Amoruso A, Monno R, Di Leo A, Ierardi E: Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol 2013, 8:169-172.
33. Bayeli PF, Mariottini M, Lisi L, Ferrari P, Tedone F: Linee guida sul dismicrobismo intestinale (SIBO: Small Intestinal Bacterial Overgrowth). Minerva Gastroenterol Dietol 1999, 45:297-308.
34. Yu D, Cheeseman F, Vanner S: Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011, 60:334-340.